S&P of ENTACT Septal Staple System for Septoplasty
S&P of ENTACT Septal Staple System for Septoplasty
This is a prospective, multi-center, single arm PMCF study to evaluate the safety and
 performance of the ENTACT (Next Generation) resorbable staple system for septoplasty in 40
 subjects. The study purpose is to provide evidence to satisfy the PMCF requirements of CE
 Marking to market this device in Europe (data may be used to support registrations on other
 countries as well).
The primary objective of this study is to demonstrate clinical success of the ENTACT (Next
 Generation) resorbable septal staple system by examining the patient's nasal cavity at the 21
 day follow-up visit.

 The secondary objectives are to generate performance and health economics data to support the
 use of ENTACT (Next Generation) resorbable septal staple.
Inclusion Criteria:

 The patient will be eligible for the study if he or she meets all of the following
 inclusion criteria at the baseline screening:

 1. Able and willing to give informed consent by voluntarily providing written informed
 consent in accordance with governing Institutional Review Board (IRB);

 2. Clinically significant deviation of the nasal septum;

 3. Willing and able to make all required study visits;

 4. Able to read and understand the approved informed consent form and patient reported
 outcome assessments (written and oral)

 Exclusion Criteria:

 The patient will be ineligible for the study if he or she meets any of the following
 exclusion criteria at the baseline screening or during surgery:

 1. Prolonged tissue approximation beyond that needed for normal tissue closure is
 necessary or desired;

 2. Traditional suturing techniques is necessary;

 3. Radiopacity is necessary or desired since ENTACT septal staples are radiotransparent;

 4. Known to be allergic to foreign body of materials of investigational product;

 5. Concomitant procedures other than turbinectomy, turbinate reduction, and/or sinus
 surgery;

 6. Pregnancy at time of procedure;

 7. Presence of infection at the site;

 8. Severe drug and alcohol abusers;

 9. Autoimmune disease deemed clinically significant by Principal Investigator (PI).